Lexaria Bioscience Corp. (NASDAQ: LEXX) remains committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. “Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes,” reads a recent article. The piece discusses significant developments Lexaria has made with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company announced plans for more trials over 2022. “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” the article quoted Lexaria’s CEO Chris Bunka as saying. “We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data.” During 2022, Lexaria is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment, and Bunka expressed optimism toward what the company terms as its largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of phase 1 and even potentially phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022.”
To view the full article, visit https://cnw.fm/rLGv3
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.